Isotechnika names Daniel Park as CBO

Isotechnika Pharma (TSX:ISA) has appointed Daniel Park to the role of chief business officer, reporting directly to CEO Dr. Robert Foster. Mr. Park will oversee all business development operations at Isotechnika, and will specifically help to lead licensing and partnership discussions and negotiations for voclosporin. He will also maintain his position as executive VP of [...]

Isotechnika partner starts uveitis Phase 3 trial

Isotechnika Pharma’s (TSX: ISA) partner Lux Biosciences has begun an additional Phase 3 trial using voclosporin for the treatment of non-infectious uveitis, a leading cause of vision loss and long-term disability. The six-month study will involve 150 patients in North America and Europe with active non-infectious intermediate, posterior, or pan-uveitis. Lux is conducting this additional [...]

Isotechnika receives financing for Phase 3 trial

Isotechnika Pharma (TSX:ISA) has finalized the development, distribution and license agreement with ILJIN Life Science, a member of the ILJIN Group of South Korea, in order to finance a pivotal Phase 3 trial of voclosporin for the prevention of kidney transplant rejection. Isotechnika will now receive a license fee of $4.5-million plus proceeds of $2.375-million from [...]

Paladin, Isotechnika submit Voclera in Canada

Paladin Labs (TSX:PLB) and Isotechnika (TSX:ISA) have submitted Voclera, a treatment for moderate to severe psoriasis, for marketing approval in Canada. Voclera was discovered by Isotechnika and has been in development since the late 1990s. Paladin acquired the Canadian rights for Voclera from Isotechnika in June, 2009. “This submission is the culmination of almost 15 years [...]

Isotechnika and 3SBio ink licence deal

Isotechnika Pharma (TSX:ISA) and 3SBio, Inc., a Chinese biotechnology company, have signed a development and commercialization agreement for Isotechnika’s voclosporin drug to prevent organ rejection following transplantation and to treat autoimmune diseases. Under the accord, Isotechnika will receive $6 million (U.S.), consisting of an upfront licensing payment of $1.5 million and an additional $4.5 million [...]

Lux-Isotechnika get complete response letter from FDA

Isotechnika Pharma’s (TSX:ISA) partner, Lux Biosciences, has received a complete response letter from the FDA about its new drug application for voclosporin in the treatment of non-infectious uveitis, involving the intermediate or posterior segments of the eye. The FDA has requested additional information and recommended that an additional clinical trial be conducted in order to [...]

Isotechnika has a powerhouse franchise in voclosporin

Dr. Robert Foster still longs to make Isotechnika’s (TSX: ISA) lead drug, voclosporin, the standard of care in the field of preventing organ rejection in transplantation surgery. This may seem somewhat unusual, since voclosporin is currently being considered by regulators in North America and Europe to treat uveitis, a chronic inflammation of the eye that [...]

« Previous Page